YOLFTbeta
Lunit Inc.

Lunit Inc.

328130 · KQ · Healthcare / Health Information Services

15,020.00KRW+1300.00 (+9.48%)

Price History

Full chart

Market Stats

Previous Close13,720.00
Open13,930.00
Day Range13,750.00 – 16,160.00
52-Week Range8,180.00 – 24,550.00
Volume3.77M
Market Cap787.02B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.23
50-Day Avg9,627.60
200-Day Avg15,204.41

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOMr. Beomseok Brandon Suh
  • Employees307
  • HeadquartersK-Square Gangnam 2, Seoul, South Korea, Korea
  • Websitehttps://www.lunit.io

Leadership

  • Mr. Anthony Seungwook PaekCo-Founder & Executive Chairman
  • Mr. Beomseok Brandon SuhCEO & Director
  • Mr. Jungin LeeCo-Founder & Dept Head of Infrastructure of Technology Innovation Group
  • Mr. Donggeun YooCo-founder, Chief AI Officer of Technology Innovation Group
  • Mr. Sunggyun ParkCo-founder and Chief Operating & Regulation Division Officer
  • Mr. Kyunghyun PaengCo-founder & Chief Product Officer of Oncology Group
  • Mr. Hyeonseong ParkChief Financial Officer
  • Mr. Jinsub BaeDept. Head of Finance & Accounting
  • Mr. Frederik Winther Struve B.Sc., J.D.General Counsel - Lunit International
  • Ms. Koren CryerDept. Head of Marketing

Financials

Income Statement

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue198.40M1.43B6.64B13.87B25.08B54.18B83.13B
Growth (%)-+620.78%+364.25%+108.85%+80.88%+116.03%+53.43%
Cost of Revenue-55.98M760.80M158.96M113.20M265.56M-
Gross Profit-1.37B5.88B13.71B24.97B53.91B83.13B
Gross Margin-96.09%88.54%98.85%99.55%99.51%100.00%
Operating Expense-22.32B51.58B64.36B67.18B121.59B166.25B
Operating Income-11.60B-20.95B-45.70B-50.65B-42.22B-67.67B-83.12B
Operating Margin-5845.84%-1465.03%-688.36%-365.30%-168.32%-124.90%-99.99%
EBITDA----34.89B-30.98B-61.83B-10.82B
EBITDA Margin----251.62%-123.53%-114.12%-13.01%
Net Income-46.97B-83.74B-73.68B-39.12B-36.80B-82.42B-47.39B
Net Income Margin-23675.02%-5855.73%-1109.74%-282.12%-146.72%-152.13%-57.01%
R&D-9.06B22.30B18.36B16.64B27.25B41.74B
R&D as % of Total Revenue-633.42%335.87%132.44%66.34%50.29%50.21%
Interest Expense-3.32B2.33B1.19B2.01B13.70B25.71B
Interest Expense % of Total Revenue-232.24%35.11%8.57%8.02%25.29%30.93%

Balance Sheet

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets38.41B25.12B93.85B97.15B267.92B435.04B369.91B
Total Liabilities97.29B155.76B91.81B28.24B32.81B270.18B232.48B
Total Equity-58.87B-130.64B2.04B68.91B235.11B164.86B137.43B
Cash-8.72B222.00K14.50B31.65B52.37B14.11B
Net Debt-----472.69M79.26B

Cash Flow

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.00B-16.75B-32.72B-53.02B-36.47B-65.70B-55.18B
Investing Cash Flow5.50B-12.77B-60.21B16.92B-145.82B-86.42B-
Financing Cash Flow36.70B2.25B99.92B34.55B199.57B171.26B-
Capital Expenditure415.94M845.71M753.12M3.96B1.59B6.67B9.63B
Free Cash Flow--17.60B-33.48B-56.98B-38.06B-72.37B-64.81B
FCF to OCF-105.05%102.30%107.47%104.36%110.16%117.46%

Earnings

Report DateSep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------
EPS Actual-308.79-275.59-37.23-177.47-221.72-216.97-183.96-267.01-188.65-1186.29-298.04-561.43-319.60-518.53-304.13-324.76
Surprise----------------
Timing----------------

Key Statistics & Ratios

Market Cap787.02B
Enterprise Value657.25B
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.57
Price / Book2.20
Revenue (TTM)91.82B
Gross Profit (TTM)91.82B
EBITDA-59.45B
Profit Margin-60.65%
Operating Margin-70.44%
Return on Equity-23.52%
Return on Assets-9.15%
Shares Outstanding74.46M
Shares Float62.89M
Beta1.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 4, 20262:1
  • Mar 18, 20262543:2378
  • Nov 9, 20232:1
  • Sep 22, 20231495:1398